LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Accueil・Liste d'Actions・Xencor Inc

Xencor Inc

Fermé

SecteurSoins de santé

11.28 0.18

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.17

Max

11.32

Chiffres clés
By Trading Economics
Revenu	-214M -129M
Ventes	-24M 4.5M
BPA	-1.71
Marge bénéficiaire	-2,854.65
Employés	260
EBITDA	-81M -75M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+114.85% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-170M 820M
Ouverture précédente	11.1
Clôture précédente	11.28

Sentiment de l'Actualité

By Acuity

34%

66%

84 / 345 Classement par Healthcare

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 mai 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 mai 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 mai 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 mai 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 mai 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 mai 2026, 22:26 UTC

Acquisitions, Fusions, Rachats

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 mai 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 mai 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 mai 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 mai 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 mai 2026, 08:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

23 mai 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 mai 2026, 21:10 UTC

Résultats

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 mai 2026, 19:47 UTC

Résultats

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mai 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mai 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mai 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 mai 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mai 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mai 2026, 18:35 UTC

Acquisitions, Fusions, Rachats

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mai 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mai 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

114.85% hausse

Prévisions sur 12 Mois

Moyen 24.3 USD 114.85%

Haut 38 USD

Bas 13 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

Achat

Maintien

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

84 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.